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Introduction:  Simple  and  efﬁcacious  delivery  methods  for inﬂuenza  vaccines  are  needed  to  improve  health
outcomes  and  manage  possible  pandemics  both  in the United  States  and  globally.  One  approach  to  meet-
ing  these  needs  is  the  microneedle  patch  (MNP),  a small  array of  micron-scale  needles  that  is applied  to
the  skin  like  a bandage.
Methods: To  inform  additional  technical  developments  and the eventual  introduction  of MNPs  for
inﬂuenza  vaccination,  we interviewed  key  opinion  leaders  in  the  United  States  for insights  into  the  oppor-
tunities  and  challenges  associated  with  this  technology,  particularly  its potential  for  self-administration.
Results:  All  interviewees  expressed  high  support  for  administration  of inﬂuenza  vaccine  in  MNPs  by
health  care  providers  and  for  self-administration  in groups  supervised  by a provider.  Self-administration
via  prescription  and  over-the-counter  purchase  of MNPs  received  lower  levels  of support.  Interviewees
also  highlighted  priorities  that  should  be  considered  in the  ongoing  development  of  an  inﬂuenza  vaccine
MNP,  such  as  conﬁrming  efﬁcacy  and  ensuring  safety  for  self-administration.  For patient  and  health  care
provider  acceptability,  important  attributes  are  ease  of use,  short  wear  times,  and an  easily  accessible
application  site.
Discussion and  conclusions:  Stakeholders  agreed  that  using  MNPs  can  help  increase  coverage,  facili-
tate  easy  and  safe  delivery,  reduce  the  cost  of  vaccination,  and  decrease  the  global  morbidity  and
mortality  associated  with  inﬂuenza.  Another  opportunity  for this  delivery  method  is  the  potential  for  self-
administration.  The  prospect  of reduced  provider  training  requirements,  increased  thermostability,  and
high  patient  and  provider  acceptability  makes  it an  attractive  option  for  use  in  remote  and  low-resource
settings  worldwide.  However,  in addition  to the  technological  challenges  associated  with  producing  the
patch, developers  must  be  mindful  of  cost  considerations  and  key  product  attributes  or  requirements,
such  as usability,  wear  time,  and  proper  disposal,  that  can affect  how  the  product  will  be  received  in  the
marketplace.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Worldwide, inﬂuenza causes approximately ﬁve million cases
f serious illness and 250,000–500,000 deaths each year [1]. If a
ighly virulent pandemic strain were to emerge in today’s inter-
onnected world, it would have the potential to kill more than 60
illion people, with a disproportionate number of deaths occurring
n low-income countries [2].
Abbreviations: KOLs, key opinion leaders; MNP, microneedle patch; OTC,
ver-the-counter.
∗ Corresponding author. Tel.: +1 2062853500.
E-mail address: dzehrung@path.org (D. Zehrung).
ttp://dx.doi.org/10.1016/j.vaccine.2015.03.062
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In the United States, annual estimates of inﬂuenza-associated
deaths between 1976 and 2007 ranged from more than 3000 to
49,000, depending on the characteristics of the circulating virus
strains [3]. Despite recommendations that all persons 6 months of
age and older be vaccinated annually, only 31% of healthy adults
aged 18–49 years, 57% of healthy children aged 6 months to 17
years, and 66% of adults aged 65 and older received a seasonal
inﬂuenza vaccine during the 2012–2013 season [4]. While many
factors inﬂuence the decision to be vaccinated, simple and efﬁ-
cacious delivery methods for inﬂuenza vaccines could improve
vaccination rates and health outcomes, and could help manage
possible pandemics in the United States and globally, especially
because the inﬂuenza vaccine must be administered every year.
An alternative delivery method is using microneedles, which
are less than one millimeter long and allow administration of
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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express for use of the MNP  for inﬂuenza vaccination in each of fourig. 1. A dissolvable microneedle patch currently in development.
hoto credit: Georgia Institute of Technology.
accines or drugs into the epidermis and dermis of the skin (Fig. 1),
ather than intramuscularly, the typical route. Intradermal delivery
f inﬂuenza vaccine by microneedles can lead to longer-lasting and
ore-robust antibody responses than intramuscular vaccination in
ice, suggesting the possibility of improved efﬁcacy [5–17]. Clini-
al studies comparing intramuscular delivery of inﬂuenza vaccine
o intradermal delivery in liquid form through hollow mininee-
les and microneedles have shown a superior immune response
n the elderly when an equal dose is administered intradermally,
nd equivalent immune responses in younger adults with admin-
stration of a reduced dose [18–24].
With the emergence of microfabrication manufacturing tech-
ology over the past several decades, microneedles have been
eveloped by academic laboratories and pharmaceutical com-
anies [25]. There are four basic types of microneedles: (1)
olid microneedles used for skin pretreatment rather than direct
rug delivery, (2) solid drug-coated microneedles, (3) polymer
icroneedles that contain the drug and release it when they dis-
olve, and (4) hollow microneedles for liquid delivery into the skin
26].
When microneedles are fabricated in arrays on a backing that
an be applied to the skin like a bandage, the device is called
 microneedle patch (MNP) [25]. Unlike hollow microneedles,
hich deliver liquid vaccine, MNPs require vaccine reformulation
nto a solid format and offer the potential for improved vaccine
hermostability (which could reduce or eliminate the require-
ent for storage in the cold chain), reduced packaging volume,
nd decreased sharps waste. Solid-coated MNPs and dissolvable-
olymer MNPs are being developed for delivery of inﬂuenza vaccine
27]. Although further research is needed to determine whether
olid MNP  delivery of inﬂuenza vaccine will allow for the use
f reduced antigen doses or improve the efﬁcacy of vaccine in
umans, there are also other potential advantages of MNP  delivery
f inﬂuenza vaccine, for example improved patient acceptability
nd the possibility of self-administration, which would allow for
ealth care provider-supervised group vaccination or unsupervised
atient self-administration as a prescribed or over-the-counter
OTC) product.
The history of commercialization efforts for other new inﬂuenza
accines provides important lessons for the introduction and
arket potential of new vaccination methods. In recent years,
ntranasally delivered, live attenuated inﬂuenza vaccine, FluMist®,
nd a preﬁlled, hollow microneedle delivery system, Fluzone
ntradermal®, have become available [28]. Each has signiﬁcant
dvantages over intramuscular delivery of inﬂuenza vaccine,
ncluding increased acceptability [29–31], and in the case of (2015) 4699–4704
FluMist®, superior efﬁcacy and cost-effectiveness [32–34]. How-
ever, neither vaccine is licensed for all age groups, and both
are priced higher than other inﬂuenza vaccines, factors which
have likely decreased their adoption rate. [32,35,36]. Research
on both FluMist® and Fluzone Intradermal® indicated that self-
administration would be feasible, but neither is currently licensed
for this [37–39].
In order to inform additional technical developments and the
eventual introduction of MNPs for inﬂuenza vaccination, we inter-
viewed key opinion leaders (KOLs) in the United States for insights
into the opportunities and challenges associated with this technol-
ogy, particularly its potential for self-administration.
2. Materials and methods
We  invited 69 KOLs nationwide with expertise in different areas
of inﬂuenza vaccination to participate in interviews about inﬂuenza
vaccine delivery by MNP. Many were current or past representa-
tives of liaison organizations for the United States Public Health
Service’s Advisory Committee on Immunization Practices or were
current or former members of that committee.
Questionnaires about the perceived beneﬁts of MNP inﬂuenza
vaccination in different delivery situations were developed, sent to
external experts for review, and ﬁnalized in an iterative process.
Each participating KOL received two questionnaires in advance of a
telephone interview. The ﬁrst was a uniform set of nine questions
for all interviewees, and the second was a set of questions tailored
to the interviewee’s area of expertise. In addition to the question-
naires, each interviewee received an information sheet on MNPs for
inﬂuenza vaccination and potential scenarios of use. Researchers
used the questionnaires to conduct a structured telephone inter-
view lasting 30–60 min  with each interviewee.
The interview questions required both quantitative and quali-
tative answers and highlighted the following areas: priority policy
issues; impact on coverage rates; acceptability to health care
providers and patients; and the importance of various product
attributes, including wear time, dissolvable versus coated MNP
technology, and thermostability. Interviewees also were asked to
list the top three issues that should be considered in the introduc-
tion of a vaccine delivery technology with the long-term goal of
self-administration. These answers were analyzed for the terms or
phrases used most frequently, which are listed as major ﬁndings in
the presentation of results.
The PATH Research Determination Committee ruled that this
activity was not a human subjects research study, and, therefore,
no ethics committee review was  conducted. Interviewees were
informed that their names would not be used in any report or
dissemination of results.
3. Results
Twenty-ﬁve KOLs agreed to be interviewed (response rate of
36%), including 10 policymakers, seven health care providers, three
waste management employees, two  state immunization program
representatives, two regulatory experts, and one purchasing spe-
cialist.
3.1. Support for different delivery scenarios
Results of the quantitative questions asking interviewees to
indicate the level of support their organizations would likelyscenarios are presented in Fig. 2. Not all interviewees answered
all questions; the number responding to each question is given in
ﬁgure legends.
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All interviewees who ranked the scenarios expressed support
or administration of the patch by health care providers, with 77%,
n a scale ranging from 1 (highest support) to 7 (highest oppo-
ition), assigning this scenario a rating of 1 and the remaining
ercentage assigning a rating of 2 (Fig. 2). For supervised group
elf-administration, support was also high, with 90% of interview-
es selecting a positive score of 1, 2, or 3 and the remaining 10%
electing the neutral score of 4. Several interviewees noted that
roup self-administration could increase efﬁciency in some loca-
ions, for example, for groups of about 10 persons in the workplace
r at colleges but not in public clinics due to perceived challenges in
cheduling and communicating with diverse patient populations.
Self-administration via prescription received positive scores
rom 79% of interviewees. Five percent of interviewees provided
 neutral response, and 16% gave a negative score to this sce-
ario. Those who were less enthusiastic about MNP  vaccination
n this setting commented that it requires an additional step for
atients—purchasing the product at a pharmacy after obtaining the
rescription from a physician—as well as uncompensated work for
hysicians.
OTC purchase for self-administration received approval from
5% of interviewees, a neutral score from 20%, and a negative
esponse from 35%—a number of whom commented on cost and/or
eimbursement issues. They noted that insured patients receive
nﬂuenza vaccine at no cost, that there is currently no reimburse-
ent mechanism for OTC purchase, and that those at highest risk
re often the least likely to be able to pay.
For a question asking for the relative ranking of four delivery
cenarios based on their perceived beneﬁt to United States public
ealth, interviewees were instructed to answer as experts in their
elds rather than as representatives of their organizations. Fig. 3
hows that no scenario received a majority of number 1 rankings;
ather, 20–30% of interviewees ranked each individual scenario as
umber 1. While more than half of the interviewees ranked OTC
dministration as the lowest option for public health beneﬁt, 30%
anked it as the highest.
ig. 2. Perceived support from health care organizations for administration of inﬂuenza v
istribution of interviewees scoring microneedle patch inﬂuenza vaccination scenarios on
nterviewees were asked to indicate the support they expected from the organizations th
cored  all scenarios): health care professional administration: 22; supervised group sel
dministration: 20. (2015) 4699–4704 4701
3.2. Key elements to consider for successful introduction of MNP
inﬂuenza vaccination
Each interviewee listed the top three issues that should be
considered for the introduction of a vaccine delivery technology
that includes the long-term goal of self-administration. The topics
mentioned most frequently are presented below, along with qual-
itative comments on these topics from the common and tailored
questionnaires.
3.2.1. Efﬁcacy and safety
Interviewees who  expressed favorable views of the MNP  com-
mented that their approval assumed that the efﬁcacy and safety
of this delivery method would be equivalent to that of existing
vaccine delivery methods, with some suggesting that a direct com-
parison of efﬁcacy with FluMist® would be useful. Some noted that
an improved safety proﬁle might be necessary for unsupervised
self-administration because inﬂuenza vaccines have been associ-
ated with anaphylaxis, syncope, and other serious adverse events
following immunization. Interviewees also noted that the demon-
stration of efﬁcacy and safety comparable to existing presentations
will be needed for regulatory approval, as well as subsequent rec-
ommendations by professional bodies, incorporation into clinical
practices, insurance reimbursement, and ﬁnally, acceptance and
uptake by patients.
3.2.2. Ease of use
Many interviewees expressed enthusiasm for the MNP  as a
potentially easy-to-use delivery technology that could save time
for health care providers administering vaccines. In order toself-administration, interviewees emphasized that the delivery
technology and application procedures should be as simple as
possible. Many noted that errors have occurred with other self-
administered products.
accine microneedle patches in different scenarios.
 a scale of 1–7, wherein 1 is highest support, 4 is neutral, and 7 is highest opposition.
ey represented. Number of interviewees scoring each scenario (not all respondents
f-administration: 21; prescription self-administration: 19; over-the-counter self-
4702 E. Jacoby et al. / Vaccine 33 (2015) 4699–4704
Fig. 3. Perceived public health beneﬁt of administration of inﬂuenza vaccine microneedle patches in different scenarios.
Distribution of interviewees ranking microneedle patch inﬂuenza vaccination scenarios on a 1–4 scale, where 1 is highest support and 4 is lowest. Interviewees were asked
to  rank scenarios in order of most beneﬁcial to least beneﬁcial for US public health, considering the potential for increasing coverage. They were not asked speciﬁcally to
represent their organization’s viewpoint. Number of interviewees ranking the scenarios (not all interviewees ranked all scenarios): health care professional administration:
1  over-
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.2.3. Cost and reimbursement
Interviewees noted that although cost is a key driver affect-
ng the vaccines offered in clinics, a slightly higher cost for the
nﬂuenza vaccine MNP  may  be acceptable. They also commented
hat reimbursement rates to providers for vaccine administra-
ion are already very low, so there is limited ability to offset
ncreased vaccine cost through administration efﬁciencies. Con-
erns were also expressed that reimbursement for administration
ees might be cut or eliminated, reducing the incentives for med-
cal care providers, pharmacies, and commercial vaccinators to
rovide inﬂuenza immunization services. Commercial vaccina-
ors and public health programs could potentially achieve savings
rom reduced cold chain requirements and increased throughput
ates when using MNPs at off-site mass clinics. In the absence of
uperior vaccine efﬁcacy for MNP  delivery, most interviewees indi-
ated that the cost of the vaccine and the reimbursement rates
ould be dominant factors in providers choosing to offer the vac-
ine.
A requirement for self-payment could adversely affect immu-
ization rates, particularly among retirees, children, and chroni-
ally ill or low-income patients. Reimbursement for OTC purchase
ould be problematic for both insurance companies and govern-
ent immunization programs.
.2.4. Education
Currently, education on inﬂuenza vaccination is provided pri-
arily by government agencies, not vaccine manufacturers. Many
nterviewees reported that the education of and marketing to
ealth care providers as well as to the general public by vaccine
anufacturers would be essential for the successful introduction
nd uptake of the inﬂuenza vaccine MNP. Education efforts should
lso reinforce the importance of receiving an annual inﬂuenza vac-
ination. In addition, health care providers and the public will need
nformation about how to use and dispose of the MNP, as well
s how to manage possible adverse events following immuniza-
ion.the-counter self-administration: 17.
3.2.5. Acceptability
Interviewees noted that a needle-free patch technology would
be highly acceptable to health care providers and patients, espe-
cially children and their parents. Needle phobia was regularly
mentioned as a barrier to vaccine uptake, as were the drawbacks of
nasally applied FluMist®. Interviewees also commented on the pub-
lic’s general familiarity with patch-delivery technology, ranging
from bandages to birth control products. High levels of acceptability
of the MNP  could, therefore, result in higher coverage rates and/or a
larger market segment. The versatility of the MNP  delivery method
was also attractive as it can be used in all the settings described in
the four administration scenarios, ranging from a physician’s ofﬁce
to the patient’s workplace or home.
3.2.6. Wear time and application site
When asked about potential MNP  wear times between 10 s and
10 min, interviewees recommended short wear times, stating that
this would increase compliance, reduce administrative burden, and
prevent errors such as early removal. They also noted that longer
wear times could reduce throughput at clinics, increase the com-
plexity of administration (requiring providers to check back in with
each patient), and require more health care provider time for super-
vision.
The placement of MNPs at sites other than the deltoid (e.g.,
forearm) should be validated and is a consideration both for
self-administration and for ensuring high throughput in clinics.
Placement at sites that do not require clothing to be removed would
facilitate group vaccinations at the workplace and in clinics and
would improve acceptability.
3.2.7. Documentation and reporting
Although vaccine registries already exist or are being developedby all states, they are not equally robust. Ensuring that a patient’s
immunization status is available to medical care providers and
for measuring immunization coverage is an important consider-
ation for self-administration, especially for OTC delivery. Lack of
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ocumentation in the OTC scenario was seen as a particular issue
or health care providers (who usually are required to be vaccinated
y their employers) and for people at higher risk of developing
nﬂuenza-related complications.
.3. Thermostability
The cold chain is a temperature-controlled supply chain from
he manufacturer to the point of vaccine delivery. The cold chain
or inﬂuenza vaccines requires maintenance of temperatures in the
ange of 2–8 ◦C. Interviewees felt that a thermostable MNP  would
ave a positive effect by reducing the large amounts of vaccine that
ypically are present for limited periods of time in the cold chain.
hermostability would also reduce storage and shipping costs and
liminate the risk of spoilage during power outages or during trans-
ort to offsite vaccination clinics. For self-administration of MNPs at
ome, thermostability also was noted as a critical attribute. Another
dvantage of MNPs that do not require refrigeration would be the
ossibility of administration by medical specialists such as cardio-
ogists, who often do not have refrigerators in their ofﬁces but could
ffer a thermostable vaccine to patients who come to them for
easons other than vaccination.
.3.1. Sharps and waste disposal
Interviewees strongly preferred MNPs with dissolvable
icroneedles to solid needles coated with vaccine because the
atter will produce sharps waste and are a potential hazard if not
isposed of properly. Also, patients could remove and dispose
f dissolvable MNPs themselves. Some respondents pointed out
hat a new technology would require following state-by-state
equirements, as each state has its own laws and regulations
hat ﬁt within the federal policy for sharps and dangerous waste.
alifornia could serve as a good model due to its conservative
isposal policies.
. Discussion
Interviewees with expertise in inﬂuenza vaccination indicated
 high level of support for MNP  delivery of this vaccine, identi-
ed a number of opportunities for the introduction of MNPs, and
ade valuable suggestions for reﬁning the target product proﬁle of
his technology, which is currently in development. Overall, results
ndicated that the easy-to-use, needle-free patch could increase
cceptance among providers and patients (particularly children),
eading to increased coverage—a major public health goal.
The limitation of our survey is the low number of KOLs
nterviewed. However, these individuals represented a variety of
rganizations, and the interviews were comprehensive.
While most interviewees were in favor of self-administration
ith the MNP, delivery by health care professionals received even
igher support. Responses on the potential for public health bene-
t from different administration scenarios trended toward bimodal
istributions, possibly indicating that some interviewees were
ore concerned with professional administration of vaccine and
thers were more concerned with getting vaccine quickly to the
argest number of people.
Since MNP  technology is still in development, opportunities
xist to create a device with a short wear time, and interviewees
dvocated for this, as it would likely reduce errors and increase
cceptability by patients and providers. Interviewees also believed
hat demonstrated efﬁcacy and safety at an accessible administra-
ion site, such as the forearm, could also improve patient ﬂow at
linics and pharmacies. Further, a thermostable product would alle-
iate pressure on the cold chain, which is especially important for
accines that are seasonal and for all vaccines distributed in low-
esource settings with limited or no electricity. Minimal, efﬁcient (2015) 4699–4704 4703
packaging will decrease space requirements for transport and stor-
age, thus reducing cold chain impact. Finally, if a dissolvable MNP
is used, needlestick injuries and sharps waste could be eliminated.
While experts expressed enthusiasm for this new product,
challenges were noted. Important next steps after technical devel-
opment is completed will include clinical studies that generate
data demonstrating the product’s safety and effectiveness for
the intended population and studies on self-administration. An
interviewee with regulatory expertise also noted that there is
currently no formal guidance or precedent for supervised group
self-administration of a vaccine in the United States. Oral typhoid
vaccine has been approved for self-administered at home, but
this involves taking a capsule rather than applying a patch to the
skin [40]. Clearly the complexities of an OTC  inﬂuenza vaccine
for self-administration will require a careful, stepwise program of
introduction.
Among the additional challenges identiﬁed by interviewees,
concerns about cost and reimbursement were foremost. As noted in
the introduction, the intranasal inﬂuenza vaccine was more expen-
sive than the injected vaccine when introduced, and this caused
decreased acceptability when insurance reimbursement was less
than the cost of the vaccine [35]. Interviewees indicated that if
the efﬁcacy via MNP  is similar to that of existing vaccines, cost
would be a major factor in whether providers choose to offer the
vaccine. Development by insurers of novel reimbursement mecha-
nisms for OTC purchases of vaccines or automatic annual renewal
of prescriptions for MNPs sent by mail to patients could facilitate
self-administration scenarios.
Although our study was conducted with stakeholders in the
United States and concerned the possible use of MNPs in this
country, the potential for reduced provider training requirements,
increased thermostability, and high patient and provider accept-
ability makes it an attractive option for eventual use in remote and
low-resource settings worldwide.
5. Conclusions
The MNP  is a promising approach to inﬂuenza vaccination, as
evidenced by the input received from KOLs with expertise in vari-
ous areas of immunization. MNPs could help to increase coverage,
facilitate easy and safe delivery, reduce the cost of vaccination,
and decrease the global morbidity and mortality associated with
inﬂuenza. A majority of interviewees agreed that MNPs have poten-
tial for self-administration, either by individuals or in supervised
groups. In addition to the technological challenges associated with
producing the patch, developers must be mindful of cost consid-
erations and key product attributes, such as usability, wear time,
and sharps disposal, which can affect how the product will be
received in the marketplace. These marketplace factors will deter-
mine whether an innovative and novel technology such as an MNP
achieves its potential and is successfully introduced with broad
uptake in the inﬂuenza vaccine market.
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